Savara

ORLANDO, Fla., May 19, 2026 Savara presented new long-term efficacy and safety data from the ongoing IMPALA-2 Phase 3...

Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...

LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...